Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Invertebrate gamma-aminobutyric acid receptor, most notably represented by the Resistant to dieldrin (RDL) subunit, is a ligand-gated ion channel that plays a fundamental role in inhibitory neurotransmission within the invertebrate nervous system. As a member of the Cys-loop receptor superfamily, it forms a pentameric structure that conducts chloride ions across the neuronal membrane upon binding the neurotransmitter GABA, thereby hyperpolarizing the cell and suppressing action potentials. This receptor is a premier target for various classes of insecticides and antiparasitics, including phenylpyrazoles like fipronil and the newer isoxazolines used in veterinary medicine. These compounds typically act as non-competitive antagonists, binding to an allosteric site within the chloride channel pore to prevent ion flow, which causes lethal hyperexcitation in pests. While these drugs are designed for high selectivity toward invertebrate receptors, potential cross-reactivity with vertebrate GABA-A receptors remains a safety consideration, and the widespread emergence of resistance mutations in the Rdl gene poses a significant challenge for pest management and vector-borne disease control.
Non-competitive antagonism of the GABA-gated chloride channel, where the drug binds to an allosteric site within the ion pore to block chloride conductance, leading to neuronal hyperexcitation, paralysis, and death of the invertebrate.
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Invertebrate gamma-aminobutyric acid receptor (RDL).